Clinical topoisomerase II poisons. The demethyl-epipodophyllotoxins (etoposide, etoposide phosphate, and teniposide), the anthracyclines (doxorubicin, daunorubicin, and idarubicin), and the anthracenedione mitoxantrone target topoisomerase II and are approved for clinical use in the United States. A scheme for the metabolism of etoposide by cytochrome P450 and oxidase is shown (top right).